Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OVID 
Ovid Therapeutics Inc (OVID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OVID (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.35% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.91M USD | Price to earnings Ratio - | 1Y Target Price 3.2 |
Price to earnings Ratio - | 1Y Target Price 3.2 | ||
Volume (30-day avg) 392251 | Beta 0.29 | 52 Weeks Range 0.30 - 3.45 | Updated Date 04/1/2025 |
52 Weeks Range 0.30 - 3.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-06 | When Before Market | Estimate -0.1671 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -14371.05% |
Management Effectiveness
Return on Assets (TTM) -30.9% | Return on Equity (TTM) -33.88% |
Valuation
Trailing PE - | Forward PE 1.79 | Enterprise Value -16180136 | Price to Sales(TTM) 44.01 |
Enterprise Value -16180136 | Price to Sales(TTM) 44.01 | ||
Enterprise Value to Revenue 37.79 | Enterprise Value to EBITDA -0.69 | Shares Outstanding 71075000 | Shares Floating 50468940 |
Shares Outstanding 71075000 | Shares Floating 50468940 | ||
Percent Insiders 16.29 | Percent Institutions 56.45 |
Analyst Ratings
Rating 4.38 | Target Price 3.26 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ovid Therapeutics Inc
Company Overview
History and Background
Ovid Therapeutics Inc. was founded in 2014. It is a biopharmaceutical company focused on developing therapies for rare neurological disorders.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for neurological disorders. Currently, they primarily focusing on research and development and do not have a marketed product at this time. Historical failures have led to pipeline restructurings.
Leadership and Structure
Jeremy Levin is the Chairman and CEO. The company has a typical organizational structure for a biopharmaceutical company with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- OV101 (Gaboxadol): OV101 was Ovid's lead product candidate for Angelman syndrome and Fragile X syndrome. Development was discontinued after failing to meet primary endpoints in clinical trials. No market share data applicable due to trial failures. Competitors would include companies with treatments for symptoms of Angelman and Fragile X syndrome, such as seizures or behavioral issues.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Positioning
Ovid is a small-cap biopharmaceutical company focused on rare neurological disorders. Due to the current lack of marketed products, its competitive advantage is limited to its intellectual property and pipeline assets.
Total Addressable Market (TAM)
TAM for rare neurological disorders is substantial, estimated to be in the billions of dollars. However, Ovid's ability to capture this market depends on successful development and commercialization of its pipeline assets, which is highly uncertain given its past failures.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on rare neurological disorders with high unmet need
- Intellectual property portfolio
- Cash reserves
Weaknesses
- Limited clinical success
- Dependence on pipeline assets
- High cash burn rate
- Lack of revenue generating product
Opportunities
- Potential for breakthrough therapies in rare neurological disorders
- Strategic partnerships with larger pharmaceutical companies
- Advancements in gene therapy and precision medicine
- Acquisition target for larger pharma
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biopharmaceutical companies
- Patent expirations
- Funding challenges
Competitors and Market Share
Key Competitors
- PTCT
- BIOX
- AVXL
Competitive Landscape
Ovid faces intense competition from larger, more established biopharmaceutical companies. Ovid's disadvantages include limited financial resources and lack of a marketed product.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Ovid's historical growth has been limited due to the lack of successful product commercialization. Its stock price has been volatile, impacted by clinical trial results.
Future Projections: Future growth projections are highly uncertain and depend on the success of its remaining pipeline programs and potential strategic partnerships. Analyst estimates are not possible without current data.
Recent Initiatives: Recent initiatives have focused on restructuring its pipeline and prioritizing programs with the highest probability of success.
Summary
Ovid Therapeutics Inc. is a high-risk, high-reward biopharmaceutical company focused on rare neurological disorders. Its future depends on the success of its pipeline programs, which is highly uncertain given past failures. The company needs to be more cost effective with cash burn and establish new partnerships to move forward.
Similar Companies
- PTCT
- BIOX
- AVXL
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and based on publicly available information. Investing in biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ovid Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-05-05 | CEO & Chairman Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.ovidrx.com |
Full time employees 23 | Website https://www.ovidrx.com | ||
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.